CLINUVEL PHARMACEUT. ORDINARY (CUV) Short Interest
CLINUVEL PHARMACEUT. ORDINARY (ASX:CUV) had 8.95% of shares reported as short positions as of 16 July 2026, representing 4,513,165 shares. CLINUVEL PHARMACEUT. ORDINARY operates in the Pharmaceuticals, Biotechnology & Life Sciences industry. Source: ASIC short position report (T+4 delay).
Source: official ASIC short position report, T+4 delay. Methodology · Disclaimer — not financial advice.
Clinuvel Pharmaceuticals
Clinuvel Pharmaceuticals Ltd. is a pioneering Australian company specializing in the development of innovative treatments for UV and light-related skin disorders. Their flagship product, SCENESSE®, is the first systemic photoprotective drug approved for preventing phototoxicity in patients with erythropoietic protoporphyria. The company leverages its expertise in photomedicine and melanocortin peptides to address unmet medical needs globally.
Short position
Price & short interest
Toggle series, zoom, and compare · ASIC daily, T+4CUV intelligence dossier
Public-source evidence for this company, with industry drill-up links.
- Tax paid and taxable income records
- Government contracts and public money
- Emissions and trade exposure
- Political donations and lobbying links
Short interest history & FAQ
Company
AI-generated research profile of Clinuvel Pharmaceuticals
Latest CUV news
All news- SCENESSE approved for EPP in Canada
asx
- Clinuvel Pharmaceuticals (ASX: CUV) Climbs on Renewed Interest: Is the Biopharma's Momentum Building? - Kalkine
googlenews
- Is Clinuvel Pharmaceuticals (ASX: CUV) Ready for a Bigger Breakout? - Kalkine
googlenews
- CLINUVEL confirms terms of CEO's Employment Agreement
asx
- CLINUVEL publicly files 20-F to U.S. SEC
asx
About
More Pharmaceuticals, Biotechnology & Life Sciences Stocks
Other shorted stocks in this sector
Be the first to discuss CUV
Start a research thread or post the first pulse update